Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 125Breast Neoplasms 82Neoplasms 78Colorectal Neoplasms 67Neoplasm Metastasis 65Prostatic Neoplasms 61Leukemia, Myeloid, Acute 61Ovarian Neoplasms 57Recurrence 55Pancreatic Neoplasms 55Multiple Myeloma 52Melanoma 40Triple Negative Breast Neoplasms 36Lung Neoplasms 36Glioblastoma 36Squamous Cell Carcinoma of Head and Neck 34Endometrial Neoplasms 33Lymphoma, Non-Hodgkin 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Lymphoma, Large B-Cell, Diffuse 28Carcinoma, Renal Cell 28Lymphoma 27Stomach Neoplasms 26Small Cell Lung Carcinoma 26Carcinoma, Hepatocellular 26Myelodysplastic Syndromes 25Lymphoma, B-Cell 25Advanced Solid Tumor 25Leukemia, Lymphocytic, Chronic, B-Cell 24Brain Neoplasms 24

Interventions

olaparib 1gedatolisib 1darolutamide 1Pluvicto 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Male Urogenital Diseases × 90 days × Clear all
NCT06785636 2026-04-24

P300

Pathos AI, Inc.

Phase 1/2 Recruiting
252 enrolled
Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡